| Market Cap | 6.88M | P/E | - | EPS this Y | 87.70% | Ern Qtrly Grth | - |
| Income | -23.53M | Forward P/E | -0.52 | EPS next Y | -0.90% | 50D Avg Chg | -31.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -41.00% |
| Dividend | N/A | Price/Book | 84.00 | EPS next 5Y | - | 52W High Chg | -71.00% |
| Recommedations | 2.50 | Quick Ratio | 0.01 | Shares Outstanding | 6.05M | 52W Low Chg | 18.00% |
| Insider Own | 25.39% | ROA | -190.98% | Shares Float | 4.92M | Beta | -0.96 |
| Inst Own | 5.72% | ROE | - | Shares Shorted/Prior | 13.88K/42.72K | Price | 0.59 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 404,258 | Target Price | 21.50 |
| Oper. Margin | - | Earnings Date | - | Volume | 103,950 | Change | 6.14% |
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
| HC Wainwright & Co. | Buy | Jan 5, 24 |
| Laidlaw & Co. | Hold | Dec 22, 23 |
| Maxim Group | Hold | Dec 19, 23 |
| Maxim Group | Hold | Dec 18, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Callahan Jennifer L. | Corporate Controller Corporate Controller | Sep 15 | Buy | 0.6697 | 5,000 | 3,348 | 45,508 | 09/18/23 |
| Callahan Jennifer L. | Corporate Controller Corporate Controller | May 12 | Buy | 1.05 | 6,000 | 6,300 | 40,508 | 05/16/23 |
| Werth Peter J. | Director Director | Dec 13 | Buy | 0.9823 | 28,934 | 28,422 | 975,165 | 12/15/22 |
| Schaffer Shane J. | Chief Executive Offi.. Chief Executive Officer | Dec 13 | Buy | 1.01 | 15,000 | 15,150 | 31,500 | 12/15/22 |
| Callahan Jennifer L. | Corporate Controller Corporate Controller | Dec 14 | Buy | 0.9894 | 7,548 | 7,468 | 34,508 | 12/15/22 |
| Callahan Jennifer L. | Corporate Controller Corporate Controller | Nov 28 | Buy | 0.98 | 5,017 | 4,917 | 26,960 | 11/30/22 |
| GIVENS GREGG WM | Director Director | Nov 22 | Buy | 0.8806 | 85,000 | 74,851 | 154,318 | 11/25/22 |
| Medeiros Curtis | Director Director | May 06 | Sell | 1.2667 | 17,532 | 22,208 | 09/23/22 | |
| Callahan Jennifer L. | Corporate Controller Corporate Controller | Sep 08 | Buy | 1.4999 | 3,500 | 5,250 | 21,943 | 09/08/22 |
| Werth Peter J. | Director Director | Sep 06 | Buy | 1.5198 | 74,500 | 113,225 | 946,231 | 09/08/22 |
| Myers Laurie | EVP and COO EVP and COO | Sep 01 | Buy | 1.57 | 636 | 999 | 47,352 | 09/06/22 |
| Myers Laurie | EVP and COO EVP and COO | Jun 01 | Buy | 1.1819 | 200 | 236 | 46,716 | 06/03/22 |
| Myers Laurie | EVP and COO EVP and COO | May 17 | Buy | 1.2079 | 200 | 242 | 46,516 | 05/19/22 |
| Myers Laurie | EVP and COO EVP and COO | Mar 16 | Buy | 1.3998 | 353 | 494 | 46,316 | 03/18/22 |
| Werth Peter J. | Director Director | Mar 17 | Buy | 1.79 | 27,000 | 48,330 | 871,731 | 03/18/22 |
| Callahan Jennifer L. | Corporate Controller Corporate Controller | Mar 16 | Buy | 1.39 | 1,900 | 2,641 | 18,443 | 03/18/22 |
| Callahan Jennifer L. | Corporate Controller Corporate Controller | Mar 14 | Buy | 1.4578 | 12,000 | 17,494 | 16,543 | 03/16/22 |
| VAN HORN LOUIS G | EVP and CFO EVP and CFO | Mar 14 | Buy | 1.3363 | 15,000 | 20,044 | 15,000 | 03/16/22 |
| Gilgallon Craig S. | EVP & General Counse.. EVP & General Counsel | Mar 14 | Buy | 1.3769 | 5,975 | 8,227 | 5,975 | 03/16/22 |
| GIVENS GREGG WM | Director Director | Mar 14 | Buy | 1.34 | 66,000 | 88,440 | 10,000 | 03/16/22 |
| Medeiros Curtis | Director Director | Mar 14 | Buy | 1.4125 | 17,532 | 24,764 | 17,532 | 03/16/22 |